These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 32401825)
1. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density? Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Chung YR; Kim HJ; Jang MH; Park SY Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931 [TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Seo AN; Lee HJ; Kim EJ; Kim HJ; Jang MH; Lee HE; Kim YJ; Kim JH; Park SY Br J Cancer; 2013 Nov; 109(10):2705-13. PubMed ID: 24129232 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. Gao G; Wang Z; Qu X; Zhang Z BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers. Woo JW; Chung YR; Kim M; Choi HY; Ahn S; Park SY Cancer Immunol Immunother; 2021 May; 70(5):1365-1378. PubMed ID: 33146829 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640 [TBL] [Abstract][Full Text] [Related]
8. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798 [TBL] [Abstract][Full Text] [Related]
9. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
10. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299 [TBL] [Abstract][Full Text] [Related]
11. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584 [TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Hu C; Tian S; Lin L; Zhang J; Ding H Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962 [TBL] [Abstract][Full Text] [Related]
17. [CD8 and FOXP3 expression in stromal tumor-infiltrating lymphocytes of triple-negative breast carcinomas: a clinicopathologic study]. Pan BJ; Ping GQ; Zhang WM; Wang C; Li HX; Zhang ZH Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):540-4. PubMed ID: 27510779 [TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer. Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921 [TBL] [Abstract][Full Text] [Related]
19. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Wang K; Shen T; Siegal GP; Wei S Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275 [TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Wang K; Xu J; Zhang T; Xue D Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]